Bladder cancer
New hope for patients progressing after prior treatment for mUCa
Educational Objective: Identify appropriate treatment options for patients progressing after prior treatment for metastatic urothelial carcinoma (UCa), a patient population who only had limited options in the past.
Specialty: Medical oncology, urology, clinical oncology, (radiation oncology)
Target Audience: CME (basic, intermediate), Residents (senior)
Latest update: December 2023
Background:
Regulatory approval status of drugs limited to the metastatic UCa setting (status 20 December 2023)
CPS: combined positive score